Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026

Integra Lifesciences Holdings Corp (IART)

A forensic read on Integra Lifesciences Holdings Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Grey Zone

Financial health

1.3

Distress distance

Clean

Earnings quality

Forensic signals

-187.1

P / E (ttm)

-49.5%

ROE

$1.3B

Market cap

0.00%

Dividend yield

1.5%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Integra Lifesciences Holdings Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 1.3, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

-13.4%

FY2025

Return on invested capital. Return on invested capital is -13.4% in the latest fiscal year and slipping from 6% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

FCF ($31M)

FY2025

Shareholder returns. Returned $221,000 to shareholders (buybacks + dividends) in FY2025, but free cash flow was ($31M) after capex — there was no free cash flow to fund the payout from at all, though operating cash flow alone was $50M — 0% of that. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.

$511M

FY2025–FY2025

Goodwill impairments. Took $511M of goodwill writedowns across 1 year (FY2025 ($511M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$1.64B

Revenue Growth YoY+1.5%

Revenue CAGR (3yr)+1.6%

Net Margin-31.6%

Free Cash Flow-$31.1M

Return on Equity-49.5%

Debt / Equity0.70x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Integra Lifesciences Holdings Corp's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.